Product development partnerships are likely to provide great opportunities for companies seeking to market biosimilar products in Brazil, where there is a huge reliance on public healthcare. Alice Rayol Sandes of Di Blasi, Parente & Associados has more.
As Mexico prepares for a presidential election in 2018, pharma IP owners are hoping that the progress made in trade negotiations is not undone. Hector Chagoya of Becerril Coca & Becerril reports.
Brazil’s patent backlog has long caused concern for IP owners, particularly those in the pharmaceutical industry, but progress is being made, as Kene Gallois and Ricardo Nunes of Daniel Legal & IP Strategy report.
Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR.
The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview.
The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.
Forming licensing agreements with other pharmaceutical companies is an important part of Pieris’s strategy, according to Ahmed Mousa, vice president of licensing, IP and legal affairs at the clinical-stage company.
Politics has a huge impact on enforcement in Africa, Asia and the Middle East, a senior corporate counsel at Pfizer has told LSIPR in an interview.
While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.
Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.